Seraxis Holdings has filed a notice of an exempt offering of securities to raise $10 Million in New Funding.
According to filings with the U.S. Securities and Exchange Commission, Seraxis Holdings is raising up to $10,000,000.00 in new funding. The federal securities law requires the notice to be filed by...
According to filings with the U.S. Securities and Exchange Commission, Seraxis Holdings is raising up to $10,000,000.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.
About Seraxis Holdings
Seraxis Holdings is a rapidly growing regenerative medicine company developing replacement cell therapies for insulin-dependent, or Type 1, diabetes. Its technology is designed to replace the pancreatic islets missing in people with Type 1 diabetes and restore normal glucose control. The company is advancing a pipeline intended to deliver a practical therapy to patients as quickly and efficiently as possible. Seraxis pursues strategic partnerships, scientific collaborations, and licensing opportunities for its technologies across different geographies and medical indications. A notable development is its definitive merger agreement with Sernova to create BetaNova Biotherapeutics, a differentiated Type 1 diabetes islet cell-replacement biotechnology company.
To learn more, visit https://seraxis.com/
LinkedIn: https://www.linkedin.com/company/seraxis/
Contact:
William Rust, Chief Executive Officer
SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved.
No Comment! Be the first one.